Laxana8 mg

Laxana is a locally-acting chloride channel activator indicated for:

• Chronic Idiopathic Constipation (CIC) in adults — an established, FDA-approved indication supported by randomized controlled trials.
• Irritable Bowel Syndrome with Constipation (IBS-C) in adult women (18 years and older) — an established, FDA-approved indication; efficacy in men has not been demonstrated.
• Opioid-Induced Constipation (OIC) in adults with chronic non-cancer pain — an established, FDA-approved indication; efficacy has not been demonstrated in patients taking diphenylheptane opioids (e.g., methadone), likely due to methadone's distinct gastrointestinal effects.

Laxana is not indicated for constipation caused by mechanical gastrointestinal obstruction, and it is not a first-line agent — it is generally used after lifestyle measures (fluid, fiber, exercise) and/or other laxatives have proven inadequate.

Each capsule contains Lubiprostone as the active pharmaceutical ingredient, available in strengths of 8 mcg and 24 mcg. Inactive ingredients typically include gelatin, sorbitol, glycerin, and other capsule-shell excipients; formulations may vary by manufacturer.

Laxana is a bicyclic fatty acid derived from prostaglandin E1 that acts locally as a selective chloride channel (ClC-2) activator on the apical membrane of gastrointestinal epithelial cells. It increases intestinal fluid secretion, softening stool and enhancing motility without altering serum electrolyte (sodium/potassium) concentrations.

It is supplied as an oral gelatin capsule and is taken with food and water to minimize gastrointestinal side effects.

Laxana belongs to the class of chloride channel activators (intestinal secretagogues), a category of laxative agents distinct from stimulant, osmotic, or bulk-forming laxatives.

Mechanism of Action

Lubiprostone selectively activates type-2 chloride channels (ClC-2) located on the apical membrane of gastrointestinal epithelial cells. This activation increases secretion of a chloride-rich intestinal fluid, which softens stool, increases motility, and promotes spontaneous bowel movements — without altering serum sodium or potassium concentrations.

Pharmacokinetics

Lubiprostone is converted rapidly and extensively in the stomach and jejunum to an active metabolite (M3), with very low systemic absorption; plasma concentrations of the parent compound are generally below the level of quantification. Metabolism occurs largely locally within the gastrointestinal tract via reduction, independent of the cytochrome P450 (CYP450) enzyme system, which accounts for its minimal drug-interaction profile.

Laxana capsules should be taken orally, twice daily, with food and a full glass of water. Swallow the capsule whole; do not crush, chew, or open it. Taking the dose with food helps reduce the chance of nausea, the most commonly reported side effect.

Laxana is metabolized locally within the gastrointestinal tract independent of the cytochrome P450 system, and systemic absorption is minimal. As a result, it has a low potential for clinically significant drug-drug interactions, and no specific interactions are well-established in labeling.

• Other gastrointestinal motility agents: Concurrent use with other laxatives, prokinetics, or drugs that significantly affect bowel motility may have an additive effect on bowel movements; monitor clinically and adjust as needed.

Always inform your physician or pharmacist of all medicines, supplements, and herbal products being used before starting Laxana.

The most commonly reported adverse effects of Laxana include:

• Nausea (the most common side effect, especially with the first dose; taking Laxana with food reduces this risk).
• Diarrhea, which may occasionally be severe (see Precautions and Warnings).
• Abdominal pain and abdominal distension.
• Headache.
• Flatulence.
• Dyspnea (shortness of breath) — uncommon, typically occurs within an hour of the first dose, generally resolves within a few hours, but may recur with repeat dosing.

Seek prompt medical attention for severe or persistent diarrhea, signs of an allergic reaction, or chest tightness/breathing difficulty.

Pregnancy: Data on Laxana use in pregnant women are limited. Laxana should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus — consult a physician before use. Women of childbearing potential should be counseled about pregnancy status and effective contraception before starting therapy, per prescribing recommendations.

Lactation: It is not known whether Laxana or its metabolites are excreted in human breast milk. Because many drugs are excreted in breast milk, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother — consult a physician before use while breastfeeding.

Severe diarrhea: Laxana may cause diarrhea, which can occasionally be severe. Discontinue use if severe diarrhea occurs and consult a physician.

Mechanical obstruction: Patients should be evaluated to rule out mechanical gastrointestinal obstruction before starting Laxana (see Contraindications).

Dyspnea: Some patients report chest tightness and shortness of breath, usually within an hour of the first dose and resolving within a few hours; it may recur with subsequent doses. Discuss with a physician if this occurs.

Nausea: Take with food and water to reduce the likelihood of nausea.

Pregnancy: See Pregnancy and Lactation.

Use only under medical supervision, and inform your physician of any history of gastrointestinal surgery, bowel obstruction, or other significant gastrointestinal disease before starting therapy.

Reported overdose experience with Laxana is limited. Doses higher than recommended have been associated with increased nausea, diarrhea, and vomiting. In case of suspected overdose, seek immediate medical attention or contact a poison control center / emergency services. Treatment should be symptomatic and supportive, with attention to fluid and electrolyte status, particularly if significant diarrhea occurs; there is no specific antidote.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and effectiveness of Laxana in pediatric patients have not been established. It is not recommended for use in children.

Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger adult patients in clinical trials; no dose adjustment is required based on age alone, though elderly patients should be monitored per usual clinical practice, particularly for diarrhea and dehydration risk.

Hepatic Impairment

A reduced starting dose is recommended in patients with moderate to severe hepatic impairment (see Dosage and Administration).

Renal Impairment

No specific dose adjustment has been established; use with routine monitoring.

Duration of treatment with Laxana should be individualized based on indication and response, as determined by the prescribing physician. Response is usually assessed within the first month of therapy; if no meaningful improvement in bowel symptoms occurs, the physician may reassess the diagnosis and treatment plan. Long-term use is common for chronic conditions such as CIC, IBS-C, and OIC, with periodic physician follow-up to confirm ongoing benefit and tolerability.

Lubiprostone is classified as a chloride channel activator / intestinal secretagogue laxative.

Lubiprostone acts locally on the luminal surface of intestinal epithelial cells to selectively activate type-2 chloride channels (ClC-2), independent of dietary intake or gastrointestinal neural stimulation. This activation increases secretion of a chloride-rich intestinal fluid, which increases intestinal fluid volume and motility, softening stool and facilitating spontaneous bowel movements, without significantly altering serum electrolyte concentrations.

C

The safety and effectiveness of Laxana in pediatric patients have not been established through adequate and well-controlled studies. Laxana is therefore not recommended for use in infants, children, or adolescents outside of a physician's specific direction. Isolated cases of accidental ingestion in children have been reported to resolve without lasting harm, but this does not establish a safe pediatric dosing regimen. Any suspected pediatric ingestion should prompt immediate medical evaluation.